Coming Attractions: New Drug Class Of 2016 Looks Strong So Far, But …
…Will industry submit enough new products in coming months to produce another year of record approval counts? Interactive chart shows new molecular entities and novel biologics with pending user fee goals.
You may also be interested in...
Even in the grip of the pandemic, review times for priority drugs were also consistent with the last three years.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker